Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers
Electrophoretic Mobility Shift Assay
Linkage Disequilibrium
0302 clinical medicine
MESH: Risk Factors
ONCOL 1: Hereditary cancer and cancer-related syndromes
Genes, Reporter
Risk Factors
Luciferases
EMC MGC-02-96-01
MESH: Genetic Association Studies
MESH: Heterozygote
ddc:610
BRCA1 Protein
MESH: Polymorphism, Single Nucleotide
MESH: Genetic Predisposition to Disease
Single Nucleotide
MESH: Genes
3. Good health
MESH: Linkage Disequilibrium
Female
Heterozygote
MESH: Mutation
610
[SDV.CAN]Life Sciences [q-bio]/Cancer
Breast Neoplasms
Polymorphism, Single Nucleotide
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
SDG 3 - Good Health and Well-being
Humans
Genetic Predisposition to Disease
Reporter
MESH: Polymorphism
Alleles
Genetic Association Studies
MESH: BRCA1 Protein
MESH: Humans
MESH: Alleles
MESH: Genes, Reporter
MESH: Haplotypes
Haplotypes
MESH: Electrophoretic Mobility Shift Assay
MESH: HeLa Cells
Mutation
MESH: Luciferases
MESH: Female
MESH: Breast Neoplasms
HeLa Cells
DOI:
10.1093/hmg/ddr388
Publication Date:
2011-09-03T00:51:14Z
AUTHORS (375)
ABSTRACT
Mutations in the BRCA1 gene substantially increase a woman's lifetime risk of breast cancer. However, there is great variation in this increase in risk with several genetic and non-genetic modifiers identified. The BRCA1 protein plays a central role in DNA repair, a mechanism that is particularly instrumental in safeguarding cells against tumorigenesis. We hypothesized that polymorphisms that alter the expression and/or function of BRCA1 carried on the wild-type (non-mutated) copy of the BRCA1 gene would modify the risk of breast cancer in carriers of BRCA1 mutations. A total of 9874 BRCA1 mutation carriers were available in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) for haplotype analyses of BRCA1. Women carrying the rare allele of single nucleotide polymorphism rs16942 on the wild-type copy of BRCA1 were at decreased risk of breast cancer (hazard ratio 0.86, 95% confidence interval 0.77-0.95, P = 0.003). Promoter in vitro assays of the major BRCA1 haplotypes showed that common polymorphisms in the regulatory region alter its activity and that this effect may be attributed to the differential binding affinity of nuclear proteins. In conclusion, variants on the wild-type copy of BRCA1 modify risk of breast cancer among carriers of BRCA1 mutations, possibly by altering the efficiency of BRCA1 transcription.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (32)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....